Multi Course: PG 2018

Introduction

The CME webinar course is provided by ENETS and based on the ENETS annual conference Postgraduate (PG) talks/webcasts from 2018. There have been held 13 talks, each resulting in a webinar of 30 min.

As UEMS/ACCME  are  accrediting 1 CME per 60 min e-learning, we provide here the whole selection of talks as webinars from which you can choose according to your specific interest.

You can choose two out of 13 topics. For each pair of chosen topics you can earn 1 European CME credit (ECMEC). 

Webinar aim

The aim is to provide learners with up to date and clinical relevant topics on NEN.

This comprises for the PG Courses held in 2018.

To learn more about each topic and its presenter please click on Learning Objectives.

Webinar will include

Two PG talks/webcasts (learners choice two out of 13 per webinar) , webinar course material (slides and references), an assessment and evaluation.

Length of webinar

60 minutes each

Date of webinar

Begin: 19 October 2018

End: 19 October 2020

Accreditation

1 European CME credit (ECMEC)

 

Disclosure

The webinar is free of advertising.

Target Audience

This webinar is intended for primary care physicians, physician assistants, and scientists in advanced clinical training (postgraduate) with an explicit interest in the treatment of gastroenteropatic neuroendocrine tumors.

Specialty fields are gastroenterology, oncology, endocrinology, pathology, as well as radiology, nuclear medicine and surgery, as there is a specific need of interdisciplinarity in neuroendocrine tumors.

Technical requirements

The webinar is easy to use and can be accessed via any internet-capable device (PC, Notebook, Tablet) on the Operating Systems Windows, MacOS, Linux, iOS and Android. The supported web browsers are Internet Explorer 9+, Microsoft Edge, Mozilla Firefox, Google Chrome and Apple Safari. All Browsers (except for Internet Explorer) are supported in the latest and second latest version.

 
 
Topic 01: GEP NET Classification: G1 and G2 – How Significant is Tumor Heterogeneity?
Lecturer: Jean-Yves Scoazec

Learning objectives

On successful completion of this activity, participants should be aware of

  • Updated classification of GEP-NENs
  • Morphological, functional and metabolic tumor heterogeneity in G1-G2 NETs and G3 NENs
  • Changes over time and clinical implications of intra- and inter-tumoral heterogeneity
Topic 02: Endoscopy and EUS: The Role in Gastric, Duodenal, Pancreatic and Rectal NETs
Lecturer: Raj Srirajaskanthan

Learning objectives

On the completion of this activity the learner should be aware

  • Endoscopy role in the diagnosis and management of gastric, duodenal and rectal NETs.
  • EUS role for histological diagnosis and characterization of pancreatic NETs.
  • EUS role for staging tumours prior to considering endoscopic resection.
  • Advances in endoscopic techniques for the diagnosis and therapy of gastric, rectal and pancreatic NETs.
Topic 03: Indications and Type of Surgery for Gastric and Duodenal NENs
Lecturer: Ulrich Peter Knigge

Learning objectives

On successful completion of this activity, participants should be able to describe

  • Classification of gastric and duodenal NENs
  • Endoscopic and surgical approaches in gastric NEN Type 1-3
  • Endoscopic and surgical approaches in duodenal NET and NEC
Topic 04: Key Points of Interventional Procedures in Radiology
Lecturer: Alban Denys

Learning objectives

On successful completion of this activity, participants should be able to describe

  • the indications of locoregional therapies in the ENETS 2016 guidelines
  • differences between the different intra-arterial therapies and their respective indications
  • what the good candidates for percutaneous ablation of liver metastases are
Topic 05: Familial GEP-NET Syndromes – Who Should We Screen and How?
Lecturer: Ashley Grossman

Learning objectives

On successful completion of this activity, participants should be aware of

  • Incidence and main features of most common Familial GEP-NET Syndromes: MEN1, Tuberous Sclerosis, Von Hippel Lindau
  • When to suspect Familial GEP-NET Syndromes and how/who to screen
  • Diagnosis and management strategy of most common GEP-NETs of familial syndromes
    (gastrinomas, insulinoma, thymic carcinoid..)
Topic 06: Familial Case Presentation
Lecturer: Gregory Kaltsas

Learning objectives

On successful completion of this activity, participants should be aware of how to approach a practical case scenario of a familial GEP-NET syndrome in the following aspects

  • Genetic testing and counseling
  • Biochemical & imaging screening in individuals at high risk for MEN1
  • Imaging modalities for pancreatic NET follow-up
  • Prognosis and survival according to MEN1 lesion; when to intervene
Topic 07: New Directions for Bronchial NET
Lecturer: Martyn Caplin

Learning objectives

On successful completion of this activity, participants should be aware about

  • Classification of lung carcinoids
  • Optimal staging of lung carcinoids
  • Surgical approach to treat localized disease
  • Role of systemic therapy in advanced lung carcinoids, including SSA, targeted therapy and chemotherapy
  • Role of PRRT in advanced lung carcinoids
  • Optimal treatment sequence and therapeutic algorythm for advanced disease
Topic 08: Refractory Carcinoid Syndrome and Other Hormonal Syndromes – How to Manage?
Lecturer: Wouter de Herder

Learning objectives

On successful completion of this activity, participants should be able to describe

  • the symptoms and implications of refractory carcinoid syndrome
  • diagnostics and differential diagnostic of refractory carcinoid syndrome (esp. diarrhoea)
  • how to manage refractory carcinoid syndrome including indications for
    – Above-label doses of conventional therapies.
    – Cytoreductive surgery.
    – Liver-directed therapies (RFA, TACE, TAE, Radioembolization).
    – Interferon alpha.
    – 131I-MIBG.
Topic 09: Preparation for Theatre: Midgut NET, Insulinoma, Phaeochromocytoma
Lecturer: David Gross

Learning objectives

On successful completion of this activity, participants should be aware of

  • Mitgut NET: how to prevent carcinoid crisis and exarcerbation of carcinoid heart disease (CHD)
  • Functional Islet Cell NET: how to prevent metabolic problems
  • Phaeochromocytoma: how to prevent hypertensive crisis
Topic 10: Theranostics for GEP and Bronchial NETs
Lecturer: Lisa Bodei

Learning objectives

On successful completion of this activity, participants should be able to describe

  • The role of 68Ga-DOTATATE in neuroendocrine tumor management.
  • The integration of 68Ga-DOTATATE PET/CT in the diagnostic and management algorithm for neuroendocrine tumors.
  • The characteristics of PRRT with 177Lu-DOTATATE, in terms of tolerability, efficacy and impact on survival parameters.
  • The role of PRRT with 177Lu-DOTATATE in the management of GEP and BP neuroendocrine tumors.
Topic 11: When Do I Choose Chemotherapy Versus Molecular Targeted Agent in G1 and G2 NETs?
Lecturer: Rocio Garcia-Carbonero

Learning objectives

On successful completion of this activity, participants should be able to describe

  • Therapeutic aims of medical therapy in G1-2 NETs
  • Principles of chemotherapy and available evidence in G1-2 NETs
  • Safety and efficacy of standard targeted therapy in G1-2 NETs (sunitinib, everolimus)
  • Chemotherapy versus targeted therapy: clinical and molecular features to consider
  • Therapeutic algorithm for advanced G1-2 pancreatic and GI NETs: ENETS Guidelines
  • Open issues and future challenges (precision medicine)
Topic 12: Should All G3 NENs Be Treated the Same?
Lecturer: Halfdan Sorbye

Learning objectives

On successful completion of this activity, participants should be able to describe

  • The terminology of GEP NEN G3 – histopathological differences among G3 NETs and NECs
  • Clinical differences among G3 NECs and NETs in terms of primary tumor location, prognosis and response to therapy (chemotherapy, PRRT, targeted therapy)
  • Role of surgery or radiotherapy in localized disease
  • Role of adjuvant therapy in localizaed disease
  • Treatment options for advanced disease G3 NECs vs NETs
Topic 13: Case Series Presentations: Unusual Sites of Metastasis: Cardiac, Brain and Orbital
Lecturer: Christos Toumpanakis

Learning objectives

On successful completion of this activity, participants should be aware of

  • Incidence and outcome of unusual sites of NEN metastasis
  • Clinical presentation and diagnostic approach of cardiac metastasis
  • Clinical presentation and diagnostic approach of brain metastasis
  • Clinical presentation and diagnostic approach of orbital metastasis
Close
Notice
Important Notice:

In preparation of the upcoming 16th Annual ENETS Conference, 6 to 8 March 2019 in Barcelona, Spain, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2019 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.